Paige Mahaney - 28 Oct 2024 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Chief Scientific Officer
Signature: /s/ Shagha Russell, Attorney-in-Fact
Issuer symbol: CCCC
Transactions as of: 28 Oct 2024
Net transactions value: $0
Form type: 4
Filing time: 29 Oct 2024, 16:31:32 UTC
Next filing: 18 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Award	$0	+76,800		$0.000000	76,800	28 Oct 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Stock Option (Right to Buy)	Award	$0	+345,600		$0.000000	345,600	28 Oct 2024	Common Stock	345,600	$6.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on October 28, 2025, subject to the Reporting Person's continued service on each such vesting date.
F2	25% of the shares underlying this option shall vest and become exercisable on October 28, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.